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to study the availability of information about the studied popula-
tion, clinical experience, pharmacokinetic properties, and drug–drug 
interactions. Using the Systematic Information for Monitoring score, 
available information was considered clinically applicable if it pro-
vided information that could be applied in clinical practice. Missing 
information was either a statement that information was absent, 
unjustifiably nonavailable information, or hollow statements (eg, 
“caution in older patients”). Descriptive statistics (frequencies) were 
applied using SPSS 20.0.
Results: The availability of relevant and clinically applicable infor-
mation ranged between 10% (Belgian Repertorium and BNF) and 
20% (FK), except for the PL (mean, 66%). The PL, which is compa-
rable to the European SmPC, appeared a more extensive document 
(7–32 pages) than the other handbooks (2 pages). In the handbooks, 
most information was present about drug–drug interactions (range, 
30%–75%). Information about patient characteristics and about 
experience in older people was present in < 7% of the handbook 
texts, except for the PL (48% and 81%, respectively). Clinically 
applicable information (what to monitor, critical value, how to 
respond) concerning renal impairment ranged from 4% to 29%.
Conclusion: This study found that the availability and clinical appli-
cability of information about older people for rational prescribing of 
medicines is incomplete in the investigated European and American 
handbooks. Because these handbooks are the primary documents 
that guide prescribing in actual medical practice, the availability and 
clinical applicability of the information on older individuals should 
be improved.
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Introduction: The aim of this study was to investigate the effect of 
chronic pravastatin treatment on diminished corpus cavernosum 
(CC) function associated with aging.
Patients (or Materials) and Methods: Male rats were divided into 3 
groups as young rats (12–14 weeks old), aged rats (72–80 weeks old), 
and aged rats given 10 mg/kg/d of pravastatin in drinking water for 
6 weeks. Systolic blood pressure (SBP) and diastolic blood pressure 
(DBP) were monitored by tail-cuff method. Total cholesterol, LDL-
cholesterol, HDL-cholesterol, triglycerides, and testosterone levels 
were estimated in blood. NO-mediated endothelium-dependent and 
neurogenic CC relaxation were evaluated by acetylcholine (ACh, 
0.1 nM–100 µM), and electrical field stimulation (EFS, 30 V, 5 ms, 
2–32 Hz), respectively. Changes in protein expression levels of eNOS, 
p-eNOS, and nNOS were assessed by immunohistochemistry.
Results: In aged rats, NO-mediated both endothelium-dependent 
and neurogenic CC relaxation was significantly impaired as com-
pared with young rats. Besides, eNOS and nNOS expressions 
decreased significantly in CC from aged rats compared with those 
from young rats. The diminished relaxation in response to ACh or 
EFS as well as reduced expressions of eNOS, p-eNOS and nNOS 
in CC of aged rats were improved by pravastatin treatment. SBP, 
DBP, and plasma levels of total cholesterol, LDL-cholesterol, HDL-
cholesterol, triglycerides, and testosterone did not change with aging 
or pravastatin treatment.
Conclusion: The present results suggest that chronic pravastatin 
treatment enhances NOS activity and NO-mediated relaxations in 
the rat CC, and this effect does not seem to be associated with lipid-
lowering effect of this drug.
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Introduction: Adverse drug reactions (ADR) in children are an 
important medical problem. The ADRs in pediatrics are not the same 
in adults. Our aim was to define such specifity for periods of child-
hood and to compare found results with ones of adults.
Patients (or Materials) and Methods: ARCADe (Adverse Reactions 
in Crimea Autonomy DatabasE) was used for search of ADRs and 
their analysis. Classification of age stages of American Academy 
of Pediatrics was used. It defines babies (0–1 y.o.), toddlers (1–3), 
preschool (3–5), and grade-school (5–12) periods of childhood, 
and teenagers (12–18). The pharmaceutical groups and drugs were 
determined using WHO ATC index. WHO classes and Naranjo 
algorithm was used in causality and FDA criteria in seriousness 
assessment.
Results: The total amount of ARCADe records in 2011–2012 
period is 2528. Amount of ADR reports for pediatric groups: 
babies, 187 (7.4%); toddlers, 138 (5.5%); preschool, 52 (2%); 
grade-school, 100 (4%); and teenagers, 52 (2%). Other reports 
were about reactions in adult patients (n = 1999, 79%). The 
amount of reports informing about ADR in male decreases with 
age. In babies, toddlers, and preschool children, ADRs in males are 
more often (55%–60%); in schoolchildren and teenagers, the ratio 
for males and females is 1:1, in adults ADRs in females are more 
frequent (60%). The most frequent clinical presentation of ADR 
in all groups is skin rash with different severity (including Lyell’s 
syndrome). In babies, rashes were found in 89.3% of cases; in tod-
dlers, in 77.5%; in preschool and grade-school children, in 75% 
and in 56%; and in teenagers, in 63.5% In adults, the frequency of 
rashes was lower (42%). The incidence of fever varied from 3.2% 
in babies to 11.4% in preschool children; then in teenagers and 
adults it decreases to 3.8% to 4%. The seriousness of ADRs was 
maximal in toddlers (75%), less in babies (71.7%); in other groups 
it was equal to adult rates (66%). The products caused ADRs most 
frequently in pediatric groups as well as in adults were antibacterial 
drugs. For them there was trend to decrease from babies (56.1%) 
to adults (36.7%) while in teenagers and adult patients the leader 
drug from this group was ceftriaxone (13.5% and 4.7%); in babies 
and toddlers ADR was mostly caused by ceftazidime (21.9% and 
12.3%). In preschool children, the leader was ibuprofen (7.7%) 
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and in schoolchildren it was atropine (8%). The “probable” and 
“possible” class of causality in babies were 57.2% and 17.1% while 
“certain” class was defined just in 24% of reports. In other groups. 
doctors were more sure in ADRs cause: “certain” class was reported 
in 50%.
Conclusion: This analysis confirms results of previous studies which 
suggest ADRs as significant issues in pediatrics, which gender speci-
fity, clinical presentations, ADR causing agent and seriousness differ 
from the same in adults.
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Introduction: Elderly people of Bangladesh have a strong belief 
that Oxalis perdicaria (Molina) Bertero as pulp or extract can con-
trol loose motion. The mechanism of action on Oxalis perdicaria 
(Molina) Bertero extract is not known but the elderly, especially 
grandmothers, use Oxalis perdicaria (Molina) Bertero extracts for 
their grandchildren who suffer from the loose motion.
Patients (or Materials) and Methods: Evaluate control of motion 
and fluid loss as affected by intake of Oxalis perdicaria (Molina) 
Bertero extract. In the observations, 29 children aged 1 to 2 years, 
having > 5 loose motions/d were randomly advised to take 60 mL 
of Oxalis perdicaria (Molina) Bertero extract (extracted from 50 
leafs with stem). The children were suffering from the persistent 
malnutrition diarrhea. They were also feed Khichdi made with 300 
g of rice, 200 g of vegetables, 2 eggs, 150 g of fish, 150 g of len-
tils, and 30 mL of soybean oil. The total amount of Khichdi was 
divided into 3 meals, and after each meal, 60 mL of Oxalis perdi-
caria (Molina) Bertero extract was given to ingest. They were also 
advised to drink oral saline in between the meals, and if capable, 
to eat fruits, such as Aegle marmelos (L.) Corrêa, Citrus maxima 
(Burm.) Osbeck, Mangifera indica L., Musa acuminata Colla, and 
Psidium guajava L. The observations were conducted at the multi-
center during October 2011 to March 2012. None was admitted to 
hospital. Urinary excretion and stool of each patient were examined 
routinely on the first day and fifth day. After 5 days, they were 
advised to eat normal diets.
Results: On the second day, 6 patients showed controlled motion 
(2–3 motions a day). Eleven cases showed controlled motion on the 
third day, 9 cases on the fourth day, and 3 cases on the fifth day. Signs 
of dehydration were absent in 18 cases on the third day, 9 cases on 
the fourth day, and 2 cases on the fifth day. Motion and dehydration 
both were controlled within the 5 days of Oxalis perdicaria (Molina) 
Bertero therapy.
Conclusion: Treatment of diarrhea with the Oxalis perdicaria 
(Molina) Bertero, a common herb in Bangladesh, is not yet estab-
lished, but the observations on 29 cases in the lessons showed 100% 
cure within 5 days. The indigenously available medicines and tech-
nologies can prove an asset in the tropical and developing countries 
of the world. At the same time, developed countries also can be 
benefited because of safety profile of the plant extracts.
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Introduction: We aimed to assess parenteral drug (PD) prescription 
patterns for children under the age of 6 at primary health care centers 
(PHCC) in Turkey, using some drug use indicators.
Patients (or Materials) and Methods: PD prescriptions were recruited 
using the databases of the year 2010 recorded in the PHCC of 32 
provinces in Turkey. One hundred PD prescriptions per month from 
each of the 32 provinces were analyzed retrospectively. Of the total 
38,400 PD prescriptions, 2369 (6.2%) were written out for children 
aged 0 to 5.
Results: PD prescriptions were more often written out for boys 
(56.8%). When age distribution was analyzed, it was found that 
PD prescriptions were most often written out for children at age 2 
(24.1%), followed by age 1 (23.3%), age 3 (17.9%), age 5 (14.5%), 
age 4 (13.6%), and age < 1 children (6.6%). Number of drugs per pre-
scription was 2.8 (1.2), number of PD per prescription was 1.1 (0.3). 
PDs constituted 57.8% of the total costs of these prescriptions. PDs 
were more often written out in winter (29.8%), followed by spring 
(27.0%), summer (24.5%), and autumn (18.7%). Most frequently 
prescribed PDs were ceftriaxone (31.6%), followed by benzathine 
benzylpenicillin (14.3%), cefazoline (8.0%) and ampicillin + sulbac-
tam (7.8%). Most frequent diagnoses on the prescriptions were acute 
tonsillitis (24.5%), followed by acute bronchitis (20.3%), acute phar-
yngitis (6.1%), and acute upper respiratory tract infection (3.8%).
Conclusion: In small children, PDs were more frequently prescribed 
for respiratory tract infection, in winter and third-generation cepha-
losporins were the most frequently prescribed PDs. The overuse of 
third-generation cephalosporins as revealed in our study represent 
a major concern for the public health because it could be associated 
with increased antibiotic resistance.
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Introduction: Literature regarding acute human toxicity of thio-
purines and mycophenolate (MMF) is limited to a handful of case 
reports. There are no published reports of sirolimus (SIR) overdose. 
The aim of this study was to investigate the circumstances and out-
comes of overdoses (ODs) with thiopurines, MMF, and SIR using 
data reported to a single national poison center.
Patients (or Materials) and Methods: A retrospective review was 
performed of all acute ODs involving thiopurines (azathioprine 
and 6-mercaptopurine), MMF, and SIR in adults and children (< 16 
years) reported to the Swiss Toxicological Information Centre (STIC) 
between 1995 and 2012.
